On July 12th, Gelunhui reported that Shandong Lukang Pharmaceutical (600789.SH) estimated that the net income attributable to the parent company's owner in the first half of 2024 would be between 2.9 billion and 3.1 billion yuan, an increase of 122% to 137% year-on-year. The net income after deducting non-recurring gains and losses that belonged to the parent company owner in the first half of 2024 is expected to be between 88.16 million yuan and 99.66 million yuan, which is 9.5 million yuan to 21 million yuan higher than the same period last year, an increase of 12% to 27% year-on-year.
(1) Main business impact: The company will continue to promote excellent performance management and optimization of product structure in 2024, steadily increase revenue, and further enhance comprehensive profitability. (2) Impact of non-recurring gains and losses: During the reporting period, the company completed the transfer procedures for the land in the southern factory area, and the overall transfer of the land will have a positive impact on the company's profits and losses.